title: An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
abstract: AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. This review outlines an overview of high-dose intravenous melphalan and stem cell transplantation in the treatment of AL amyloidosis. An algorithm of our recommendations for the treatment of AL amyloidosis is also outlined.
authors.affiliation: Section of Hematology/Oncology in the Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA. Vaishali.Sanchorawala@bmc.org
authors.forename: Vaishali
authors.initials: V
authors.lastname: Sanchorawala
authors.forename: David C
authors.initials: DC
authors.lastname: Seldin
mesh_terms: D000465:Algorithms; D000686:Amyloidosis / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use*; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D033581:Stem Cell Transplantation / Q000379:methods*
chemical_list: D019653:Myeloablative Agonists; D008558:Melphalan